IKZF1 and neoplasm: Similarly, IKZF1 (Ikaros) deletions or dominant-negative isoforms compromise its tumor-suppressive enhancer-silencing function, permitting SE-driven expression of cytokine receptors (CRLF2) and kinases (JAK2) (Raca et al., 2021; Mullighan, 2011).